Xenetic Biosciences, Inc.

Home
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is

initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

14/07/2025

: James F. Parslow, Interim CEO & CFO, brings 35+ years of leadership across biotech, clean tech, e-commerce and high-tech manufacturing.

He’s led strategy, capital markets, M&A, and investor relations with a strong track record of driving growth and performance.

🔗 Read more: https://bit.ly/4dd8mx0

11/07/2025

Stay in the know with XBIO! 🚀
Get email alerts and be the first to hear about our latest news, updates and breakthroughs.

Sign up today and never miss an update!
https://bit.ly/3MTgAiR

08/07/2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

https://bit.ly/40Hrdwq

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

04/07/2025

Wishing everyone a safe and happy Independence Day!

27/06/2025

Explore our innovative oncology pipeline—designed to address multiple cancer indications with a differentiated, targeted approach.

Take a closer look at our pipeline here: https://bit.ly/3PkEMfi

24/06/2025

Our latest corporate presentation highlights the science, strategy, and momentum driving forward.

Explore now: https://bit.ly/4dIDvdB

20/06/2025

: Dr. Reid Bissonnette, Executive Consultant, shared key takeaways from encouraging preclinical data.

Check it out here: https://vimeo.com/1073730956/87d390651d?ts=0&share=copy

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society…

16/06/2025

At Xenetic, we're focused on advancing our systemic DNase program into the clinic—aiming to develop it as an adjunctive therapy for pancreatic carcinoma and other advanced .

11/06/2025

Our lead program has the potential to overcome T cell exclusion and immunosuppressive signals by the tumor microenvironment. We remain committed to unlocking new possibilities in the fight against cancer—and to making a meaningful impact for patients who need it most.

01/06/2025

On , we recognize the resilience of cancer survivors and the journeys that define them. Their strength inspires us to keep pushing boundaries in cancer research and care.

29/05/2025

Advancing Innovative Immune-Oncology Technologies

23/05/2025

Xenetic Biosciences is committed to advancing the translational potential of our approach—striving to offer patients a much-needed alternative that addresses key unmet needs in cancer treatment.

Address

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Shortcuts

Address
Telephone
Alerts
Contact The Practice
Claim ownership or report listing
Want your practice to be the top-listed Clinic?

Country:

City:

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.